NervGen Pharma Corp. NGEN.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.92M | -30.09M | -31.62M | -18.46M | -19.46M |
| Total Depreciation and Amortization | 40.40K | 40.40K | 39.90K | 41.20K | 41.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -405.80K | 14.09M | 17.14M | 5.29M | 6.07M |
| Change in Net Operating Assets | -2.29M | -1.12M | 466.00K | 1.14M | 989.20K |
| Cash from Operations | -18.57M | -17.08M | -13.97M | -11.99M | -12.35M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.50K | 60.70K | 72.20K | 72.10K | 72.30K |
| Cash from Investing | 42.50K | 60.70K | 72.20K | 72.10K | 72.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -58.80K | -84.00K | -100.80K | -100.80K | -100.80K |
| Issuance of Common Stock | 104.86M | 25.84M | 24.76M | 8.12M | 7.31M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.14M | -483.10K | -892.80K | -685.40K | -604.80K |
| Cash from Financing | 71.22M | 18.19M | 17.05M | 5.27M | 4.74M |
| Foreign Exchange rate Adjustments | -1.42M | 224.80K | 312.90K | -225.30K | -284.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 51.27M | 1.40M | 3.47M | -6.88M | -7.82M |